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In vitro induction of human cytotoxic
T lymphocyte responses against peptides of
mutant and wild-type p53*
The central role of the p53 tumor suppressor gene product in oncogenesis is
gradually being clarified. Point mutations in the p53 tumor suppressor gene are
common in most human cancers and are often associated with p53 protein
overexpression. Overexpressed wild-type or mutant determinants of the p53
protein thus represent an attractive target for immunotherapy of cancer directed
against a structure involved in malignant transformation. An important step
towards this goal is identification of epitopes of p53 that can be recognized by
human cytotoxic T lymphocytes. We identified peptides of (mutant) p53 capable
of binding to HLA-A2.1 in an in vitro assay. These HLA-A2.1-binding peptides
were utilized for in vitro induction of primary cytotoxic T lymphocyte responses
using a human processing-defective cell line (174CEM.T2) as antigen-presenting
cell. These cells display "empty" HLA class I surface molecules, that can
efficiently be loaded with a single peptide. We obtained CD8+ cytotoxic
T lymphocyte clones capable of specifically lysing target cells loaded with
wild-type or tumor-specific mutant p53 peptides. This strategy allows the in vitro
initiation of human cytotoxicT lymphocyte responses against target molecules of
choice.
1 Introduction
The promise of T cell therapy of human cancer is looming
large, but has not been fulfilled [1,2]. Recently murine
models demonstrated the potential of therapy with ex vivo
cultured cytotoxic T lymphocytes [3, 4]. Human tumor-
specific CTL have been cloned out of peripheral blood or
tumor-infiltrating lymphocytes from patients with melano-
ma [5] and renal cell carcinoma [6]. In some cases the
molecular identity of the tumor-associated antigens of
these CTL has been elucidated ([17],Th. Boon, personal
communication). Instead of natural immunity or immuni-
zation with tumor cells or protein, a reverse strategy aimed
at generating T cell immunity against a precisely defined
epitope in a tumor-associated target protein of choice
seems preferable [2]. This strategy offers the advantage of
targeting on molecules intrinsically associated with the
growth deregulation characteristics of tumor cells. More-
over this approach allows the arousal of a repertoire of
T cells against cryptic epitopes that is not normally evoked
by immunization with whole antigen [8]. T cell repertoires
against subdominant autologous epitopes usually are not
subject to clonal deletion [8, 9].
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CTL recognize peptide fragments of cellular proteins
bound in the antigen-presenting groove of MHC class I
molecules [10]. In vitro peptide induction of primary CTL
responses has been achieved with synthetic peptide-loaded
murine dendritic cells [11, 12] or mouse processing-defec-
tive RMA-S cells [13] as APC. To induce human CTL
responses we utilized peptide-loaded human processing-
defective ceils, 174CEM.T2 (T2) [14], with properties
comparable to those of RMA-S cells. Our strategy of
eliciting primary CTL responses in vitro includes the
following steps: (1) selection of amino acid sequences in
target proteins of choice that match peptide motifs for
binding to HLA class I [15,16], using a computerized
scoring system, (2) testing of actual binding to HLA class I
of these peptides [15, 17], (3) in vitro induction of CTL
responses against binding peptides, (4) investigation of
antigen processing of the chosen target protein using the
generated CTL clones and (5) adoptive transfer of the
tumor specific CTL [4].
Only few potential target antigens for T cell therapy of
human cancer have been identified. Among these is the
MAGE family of proteins expressed in melanoma and
other tumors [18]. The p53 tumor suppressor gene product
might represent another attractive target for CTL therapy.
The central role of p53 in oncogenesis is gradually being
clarified [19]. In the majority of human cancers the function
of p53 is severely impaired by diverse mechanisms [20].
Point mutations in the p53 gene are often associated with
p53 overexpression caused by the decreased breakdown of
the tetrameric form with mutant components j21].This may
lead to abnormal presentation of p53 to the immune system
as evident from the occurrence of p53-specific autoantibod-
ies in patients bearing tumors with p53 overexpression [22].
We therefore concentrated on in vitro induction of CTL
clones against both (overexpressed) wild-type p53 and
(tumor-specific) mutant p53.
We previously reported on a scoring system predicting
peptide binding to HLA-A2.1 and an in vitro peptide
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2.3 Peptide binding assaybinding assay [15]. We now demonstrate that in vitro
induction of primary CTL responses is feasible and that
CTL against autologous and mutant epitopes of p53 can be The peptides were synthesized by solid-phase strategies on
raised. an automated multiple peptide synthesizer (Abimed
AMS 422) using Fmoc-chemistry and HPLC checked for
contaminants. Peptides were dissolved in PBS, pH cor-
rected , brought to a peptide concentration of 4 mg/ml and
2 Materials and methods
2.1 Peptide scoring system
We recently published a computer scoring system for
predicting peptide binding to HLA molecules [15]. Briefly,
for peptide binding to HLA-A2.1 the scores are based on
the 9-amino acid HLA-A2.1-restricted peptide motifs
[23, 24], These motifs designate leucine, isoleucine or
methionine at position 2 and an aliphatic residue (valine.
leucine, isoleucine or alanine) at the C terminal end
(position 9) as anchor residues in addition to various
"strong" and "weak" motif residues at other positions.
Peptide binding studies, performed since our recent report
[15], with a variety of unselected overlapping 9-, 10- and
11-mer peptides from several proteins showed that at the C
terminal end cysteine and threonine can also be designated
as anchor residues [unpublished observations, J.G.A.H.,
H.W.N., W.M.K., M.C.W. Feltkamp (Leiden) and
C.J.M.M.]. Our scoring system assigns 6. 4 or 2 points for an
anchor, a strong or a weak residue match, respectively.The
scores of all 9 amino acids are multiplied to reach the final
peptide score. Peptides lacking anchor residues at posi-
tion 2 and the C-terminal end were discarded. The scoring
for 10- and 11-mer peptides was performed similarly, but
multiple anchors at positions 9,10 or 11 within one peptide
were scored only once. A correlation can be expected
between high score and binding to HLA-A2.1, which is
exemplified by the observation that all HLA-A2.1-
restricted CTL epitopes [25, 26] analyzed by us score over
71 points.
2.2 Cell lines and cytotoxicity assay
The 174CEM.T2 (T2, a gift from R Cresswell, Dept. of
Immunology, Yale University, New Haven, CT) cell line
showing no HLA-B5 and low HLA-A2.1 surface expres-
sion [14] was cultured in Iscove's modified Dulbecco's
medium (IMDM) with 2 mM glutamine, 100 ID/ml penicil-
lin, 100 fig/ml kanamycin and 10 % PCS.
TheT2/TAPl+2 cell line is theT2 cell line transfected with
the genes encoding for the subunitsTAPl and TAP2 [27] of
a putative peptide transporter. T2/TAP1+2 cells have
restored HLA class I surface expression and show HLA
class I-restricted antigen presentation [28,29]. The
T2/TAP1 cell line was transfected with only the gene for the
TAP1 subunit of the TAP heterodimer and showed proper-
ties comparable to those of T2 [28].
The cytotoxicity of CTL against sensitized target cells was
tested in a standard 4-h 51Cr-release assay. The peptide was
loaded onto the target cells during 10 min before the assay
and was present in the medium during the assay. All
HLA-A2.1 positive cell lines were effectively lysed by an
HLA-A2.1 alloreactive CTL clone [30].
stored at -20 °C.
The T2 in vitro peptide binding assay was published
recently [15]. Briefly, T2 cells were washed twice; 80000 T2
cells in 40 ul serum-free IMDM medium and 10 ul synthetic
peptide (final peptide concentration in well: 50 ng/ml) were
incubated overnight. After incubation the T2 cells were
washed and stained successively with the HLA-A2 specific
mouse monoclonal antibody BB7.2 and FITC-labeled
F(ab')2 fragments of poiyclonal goat anti-mouse IgG.
Fluorescence of viableT2 cells was measured at 488 nm on a
FACScan flow cytometer. The fluorescence ratio was
calculated by the formula: mean fluorescence experimental
sample/mean fluorescence background. A fluorescence
ratio higher than 1.2 correlated with an experimental
sample mean fluorescence higher than background mean
fluorescence plus 2 standard deviations. Binding of the
synthetic peptides was tested in at least three separate
assays and was highly reproducible.
2.4 In vitro CTL induction protocol
T2 cells - to be used as APC - in a concentration of 2 X 106
cells per m! were incubated overnight with 80 ug/ml peptide
at 37 °C in serum-free IMDM medium with 2 mM gluta-
mine, antibiotics [100IU/ml penicillin (Brocases Pharma,
Leiderdorp,The Netherlands), 100 (ig/ml kanamycin (Sig-
ma, St. Louis, MO)]. After peptide incubation the T2 cells
were treated with mitomycinC to prevent proliferation.
After triple washing in RPMI (Gibco, Paisley, Scotland) 105
peptide-loaded T2 cells in 50 ul standard medium with
80 ng/ml peptide were seeded into each well of a 96-well
U-bottom culture plate. Standard medium is RPMI, glu-
tamine (2 mM) and antibiotics. Responder cells were Ficoll
(Lymphoprep, Nycomed-pharma, Oslo, Norway) discon-
tinuous gradient separated PBMC from an HLA-A2.1
subtyped healthy individual. Washed PBMC (4 x 105) in
50 |*I standard medium with 30 % pooled human serum
(tested and found negative for suppression activity in mixed
lymphocyte cultures) were added to the peptide-loaded T2
cells and cultured at 37 °C in an incubator (5 % CÜ2 and
90 % humidity). On day 7 the responding, viable PBMC of
all 96 wells were harvested on Ficoll. "Responder cells"
were seeded into a 96-well culture plate: 5 x 104 responder
cells in 50 ^1 standard medium with 30 % pooled human
serum per well. Per well 2 x 104 cryopreserved, autolo-
gous, irradiated (2500 rad) PBMC and 104 autologous,
irradiated (5000 rad) B-LCL in 50 (*1 standard medium with
80 ug/ml peptide were added. On day 14 a similar restimu-
lation was performed. On day 21 viable responder cells
were harvested on Ficoll and washed in RPMI. This bulk
was cloned by limiting dilution: 10 or less responder cells in
50 \il standard medium with 30 % pooled human serum
were seeded per well. As stimulators (APC) and feeders,
2 x 104 pooled and irradiated (3000 rad) PBMC from at
least three different donors and 104 pooled and irradiated
(10000 rad) B-LCL from at least two different HLA-A2.1
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Position3* Scoreh> Peptides FRc!
129-137 288 ALNKMLCQL 1.4
129-137 288 ALNKMFYQL 1.2-
132-140 192 NMFCQLAKT 1.5
132-140 384 KLFCQLAKT 1.3
132-140 384 KMFYQLAKT 1.3
168-176 1152 17: HMTEVVRHC 1.3
187-197 288 GLAPPQHF1RV 1.2-
264-273 288 LLGRNSFEVCV 1.2-
264-274 288 LLGRNSFEVC 1.2-
a) Position of the peptide in the amino acid sequence of p53.
b) Arbitrary score of our scoring system . based on peptide motifs.
Only 9-, 10- or 11-mer peptides scoring over 71 points with two
anchor residues have been synthesized; see Sect. 2.1.
c) Fluorescence ratio of at least three separate peptide binding
assays; see Sect. 2.3. — A weakly binding peptide.
The underlined letter marks the point mutation. A8, 17:
peptides chosen for further studies; D6. B7 control peptides.
as "responders" cells. Protocols with different types of APC
subtyped donors resuspended in 50 uj standard medium
with 2% leuco-agglutinin (Pharmacia, Uppsala, Sweden),
human recombinant IL-2 (240 lU/ml, Eurocetus, Amster-
dam,The Netherlands) and peptide (40 ng/ml) were added
per well. Growing clones were expanded.
3 Results
3.1 Scoring of (mutant) peptides of p53 and actual
binding of selected peptides
Computerized application of the scoring system to the 393
amino acids of wild-type p53 [31] and the 20 amino acids
around each one of 32 published point mutations in
colorectal and ovarian cancer (references available)
resulted in a minority of p53 peptides scoring over 71 points
and having two anchor residues: 41 peptides (14 9-mer,
15 10-merandl2 11-mer) out of the 1152 possible wild-type
peptides and 22 peptides (11 9-mer, 7 10-mer and 4 11-mer)
out of the 960 possible mutant peptides.
These 63 potentially binding peptides were synthesized and
tested for actual binding. The peptides that bind to
HLA-A2.1 are shown in Table la. Eighteen of the 41
selected peptides (44 %) of wild-type p53 appeared to bind:
7 9-mer. 6 10-mer and 5 11-mer peptides, whereas 9 out of
the 22 selected mutant peptides (41%) of p53 showed
binding properties to HLA-A2.1 (Table lb).
3.2 Comparison of different in vitro protocols for CTL
induction
Several in vitro protocols for CTL induction have been
compared to find optimal conditions. We used in all
protocols PBMC from HLA-A2.1-positive healthy donors
(T2,T2/TAPl,T2/TAPl+2 or PBMC) loaded with either
40 u,g/ml or 0.4 u.g/ml peptide and with responder cells
being or not harvested on Ficoil were run in parallel
(Table 2). The bulk cultures did not exert any cytotoxicity.
During the bulk stimulations the "high peptide" and
"Ficoil" protocols resulted in the lowest yields of "respon-
der" cells. The "Ficoil" and *T2" protocols resulted in the
lowest cloning efficiency (data not shown). Only T2 cells
loaded with a high concentration of peptide combined with
harvesting of responder cells on Ficoil generated stable,
peptide-specific CTL clones (Table 2). The generated CTL
clones areTcRo/p+, CD2+, CD3+, CD8+, CD25+, MLA-
DIC, HLA-A2+ and CD16~ (data not shown).
PBMC used as responders cells were depleted of CD4+ cells
before start of the CTL induction to test whether CD4+
lymphocytes are essential for this protocol, induction
Table 2. Comparison of different CTL induction protocols
APC Cln-CTX°)
a) Harvesting of responders cells +/— on Ficoil.
b) High (40 (ig/mi) or low (0.4 (ig/ml) peptide concentration.
c) Number of stable, peptide specific CTL clones generated.
d) The responder PBMC were depleted of CD4+ cells.
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without CD4+ responder cells generated stable, peptide-
specific CTL. Utilization as APC of T2/TAP1 +2 cells, that
have restored antigen processing and HLA class I surface
expression, failed to generate stable CTL clones, whereas
T2/TAP1 cells, that are functionally comparable to T2,
could act as useful APC (Table 2).
HLA-A2.1 binding peptide of p53 with an arginine to
histidine mutation common in colon [32] cancer (peptide
17: p53{168-176,175H} see Table Ib). The CTL clone
10F10, shown in Fig. 2. does not lyse target cells that are
sensitized with the wild-type p53{ 168-176} peptide (B7)
and is therefore able to recognize a tumor-specific anti-
gen.
3.3 CTL clones against wild-type and mutant p53
peptides
Examples of in vitro induced CTL clones are 1A5 and 3C5
which recognize p53 {264-272} (A8, Table 1 and Fig. 2).
The CTL clones show dose-response relationships in lytic
capacity (Fig. l).To check whether the specificity of CTL
was not directed against a contaminant, the A8 peptide was
FTPLC purified and successfully used to sensitize target
cells (Fig. 2). HLA-A2.1 restriction of the CTL clones was
confirmed by blocking of T2-directed lysis with the anti-
HLA class I mAb W6/32 (data not shown) and by lack of
lysis of A8-sensitized HLA-A2.1~ EBV-transformed lym-
phoblastoid B cells (LCL, Fig. 2). Cytotoxicity of the
clones was also blocked by incubation of the CTL with an
anti-CD8 mAb (data not shown).
The fine specificity of the CTL was studied by alanine and
arginine replacements in the synthetic A8 peptide. Resi-
dues at positions 2,3,9 and to a lesser extent 6. 7 influence
peptide binding to HLA-A2.1, whereas replacements at
positions 4, 5 and 8 interfere with recognition by the T cell
receptor. Substitutions at positions 6 and 7 might also affect
CTL recognition (Table 3).
Using the same induction protocol we primed HLA-
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Figure I. Dose-response relationship of cytotoxicity of two CTL
clones that were induced in vitro against peptide AS
(p53{264-272} see Table la) in a standard 4-h 51Cr-release assay.
Target cells: T2 cells (T2) loaded with 20 ug/ml down to 2 ng/ml AS
peptide, with 20 ng/ml of the HLA-A2.1 binding p53{65-73)
peptide (D6) or with PBS alone (0). The effector-to-target ratio
[E/T] was 10:1 and the peptide concentration (ng/rnl) was 20 fig/ml
except where indicated otherwise.
targets ^s/ni)


















Figure 2. Standard 4-h 51Cr-release cytotoxicity assay of two CTL
clones specific for peptide A8 (p53 (264-272)) and one CTL clone
specific for peptide 17 {p53{168-176.175H}) with several types of
target cells. T2 cells (T2). antigen presentation restored T2 cells
(T2/TAP1+2), PHA blasts (PHA) or B-LCL (LCL) with HLA-
A2.1+ or HLA-A2.1" (A2neg.) phenotype.The effector-to-target
ratio was 10:1 and the peptide concentration 20 (ig/ml, except for
"T2+A8 HPLC" were the T2 target cells were sensitized with
HPLC-purified A8 peptide. CTL against the mutant p53 peptide 17
do not lyse peptide B7 (wild-type p53 {168-176})-sensitized target
cells.
Table 3. Amino acid replacements in p^3 {264-272}a
anine replacement
L L G R N S F E V
Arginine replacement
L G R N S F £ V
± - + + - - ±
a) Amino acid replacement study. Every single amino acid in the
A8 peptide was replaced sequentially by alanine or arginine. Of
all 17 different peptides the binding to HLA-A2.1 in the T2
peptide binding assay was assessed.T2 cells were peptide loaded
(20 ug/ml) and used as target cells in a standard 51Cr-release
cytotoxicity assay to study recognition by the AS-specific CTL
clone 1D5 in an effector-to-target ratio of 10:1. Symbols: + for
high, ± for moderate and — for no binding or cytotoxicity.
Moderate binding is a fluorescence ratio below 1.5 and
moderate cytotoxicity is lysis between 20% and 60% of the
maximum lysis.
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4 Discussion
The pre-selection of peptides with the computerized
scoring system is useful [15, 33], since out of 2112 possible
peptides of (wild-type and mutant) p53, 63 peptides were
selected, over 40% of which showed actual binding to
HLA-A2.1. Ten- and 11-mer peptides were shown again to
be among HLA-A2.1 binding peptides [33]. Furthermore,
these first two steps of our reverse strategy resulted in
precise prediction of HLA-A2.1-restricted epitopes since,
comparable to murine models [34-36], the peptides (AS
and 17) that were randomly chosen from the well-binding
9-mer peptides appeared to serve as CTL epitopes.
We achieved in vitro induction of CTL responses against
binding peptides using T2 or T2/TAP1 cells as APC.
Utilization of T2 as an APC is comparable to the murine
protocol that uses the RMA-S cell line as APC [13]. The
capacity of RMA-S cells to induce CTL is ascribed to the
high number of MHC molecules presenting the same
peptide [12, 37] and the virtual absence of MHC class I
molecules presenting other peptides [38-40], BothT2 and
RMA-S show increased surface expression of MHC after
exogenous loading with a single peptide that binds to MHC
Class I [15,41-43]. Exogenous addition of HLA-A2.1
binding peptides to T2/TAP1+2 cells or HLA-A2.1+
PBMC did not result in significantly increased HLA-A2.1
expression, whereasT2/TAP1 cells have cell surface expres-
sion comparable to that of T2 (data not shown). We
conclude that under the circumstances of our human
protocol a high number of relevant peptide/MHC com-
plexes on the cell surface is important for in vitro CTL
response induction. This is comparable to the murine model
of De Bruijn et al. [12]. This induction of CTL precursor
cells does not seem to be dependent on help from CD4+
ceils, since CD4-depleted PBMC responders resulted in
CTL clones as well (Table 2). An influence of irradiated
CD4+ cells, present among the feeder cells during the
re-stimulations (2nd and 3rd week) can not be excluded. De
Bruijn et al. showed that in the mouse primary CTL
response induction by peptide-loaded dendritic cells or
RMA-S cells is CD4+ T cell independent [12].
Our strategy may be helpful to select by in vitro methodol-
ogy peptides (epitopes) that are suitable for peptide-based
vaccines for human cancer. In a mouse model, a peptide-
based vaccine, selected on the basis of MHC class I binding
capacity, was shown to prevent outgrowth of tumors
(Feltkamp, M.C.W. et al., manuscript submitted).
The alanine and arginine replacement study defined the
binding requirements of AS to HLA-A2.1 and the fine
specificity of the A8 specific clones. The importance of
positions 2, 3. 9 and to a lesser extent 6, 7 for peptide
binding is reflected in the published peptide motifs for
HLA-A2.1 [23, 24, 26] and other replacement studies [33].
The amino acid side chains at positions 4, 5 and 8 (and
possibly 6, 7) seem essential for TcR recognition which
largely confirms previous reports on HLA-A2.1 restricted
CTL [25, 26]. Our in vitro human CTL induction protocol
might be a useful tool in studies on the precise composition
of the TcR, e.g., Va, Vp usage [44] and their precise
sequences, of human class I-restricted CTL. From PBMC
of a single donor several CTL clones could be generated
against peptides that only differ in one amino acid.
Our A8 (p53 wild-type)-specific CTL clones supplement
observations of T cell responses against autologous struc-
tures [22, 45]. Nonresponsiveness for the self antigen p53
in vivo can result from several mechanisms: (1) clonal
deletion of p53 reactive T cells, (2) anergy or suppression of
established CTL, (3) localization of the self antigen or (4)
absent or insufficient antigen processing. It has already
been stated that tolerance only exists towards dominant
epitopes. whereas the repertoire against "cryptic" self
epitopes is largely intact [8, 46],
The AS-specific CTL disprove clonal deletion (1) while a
possible anergic state of the CTL (2) might have been
overcome in the induction protocol [47], although the CTL
most probably result from a primary induction by our
in vitro protocol. In our study we even have observed that
induction of primary CTL responses against the wild-type
p53 (self) peptide was easier, more efficient, than induction
against the mutant p53 (foreign) peptide. P53 is present in
every cell (3) at very low concentration [19], but the clones
specific for peptide A8 are not capable of lysing
T2/TAP1+2 cells, PHA-blasts and B-LCL without peptide
loading. Absence or insufficiency of processing and presen-
tation (4) of the CTL epitope (AS) is a possible explanation
for the lack of lysis of non sensitized "normal" cells. A
murine model snowed that autoreactive (cytochrome c)
T cells escape tolerance when the self-peptide lacks pro-
cessing [48]. Alternatively, the epitope can be presented at
levels insufficient for recognition [9, 49, 50] by the A8-
specific CTL clones. The AS-specific CTL clones could be
blocked with an anti-CDS mAb, which has been associated
with "low-affinity" T cell receptor [37, 51, 52].
In the case of tumor cells with overexpression of p53,
specifically under conditions of abnormal routing of p53
through the cytoplasm [53], the processing might be
qualittvely and/or quantitively different. IgG autoantibod-
ies against overexpressed p53 in breast cancer patients have
been reported [22] indicating activation of CD4+ T helper
lymphocyte responses. Since we can exclude clonal deletion
of all AS peptide specific CTL, a primary or even secondary
T cell response may be inducible from PBMC of HLA-
A2.1+ (40% of the Caucasoid population) patients with
p53 overexpressing tumor.
The CTL specific for the mutant peptide of p53 are tumor
specific because they do not recognize the correspond-
ing wild-type peptide. A single point mutation resulting in
one amino acid replacement appears sufficient to differen-
tiate between a normal and a tumor-specific peptide.
Recognition by these CTL of tumor cells depends on the
presence of the particular mutation, the restriction element
and sufficient processing and presentation. Our 17
(p53{168-176,175H})-specific CTL clones demonstrate
that in vitro induction of human primary CTL responses
against a (molecularly defined) tumor-specific epitope is
feasible. Previous reports on in vitro induced T cell re-
sponses concerned non cytotoxic, CD4+, HLA class II-
restricted T cells that proliferate upon stimulation with
peptides of point-mutated ras protein [54, 55].
In conclusion, selection of HLA class I-restricted epitopes
from a target molecule of choice is possible and in vitro
peptide-mediated induction of human CTL clones is feasi-
ble. These or other CTL clones directed against the
Eur. J. Immunol. 1993. 23: 2072-2077 In vitro induction of CTL against peptides of (mutant) p53 2077
above-mentioned peptides may be capable of selectively
lysing tumor cells with the relevant mutation of p53 or
overexpression of p53. Such CTL are potentially useful for
cellular immunotherapy of cancer.The same strategy can be
applied to other molecularly defined HLA-binding epi-
topes in target proteins of choice.
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